Loading
A phase 3 trial of Filgrastim and Plerixafor in Non-Hodgkin lymphoma, run by Sanofi, completed.
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation is a phase 3 interventional study registered as NCT01767714 by Sanofi, with 100 participants recorded, started 2013-04 and reaching its primary completion in 2014-11. Interventions recorded: Granulocyte-colony stimulating factor (G-CSF), Plerixafor, Placebo. Conditions recorded: Non-Hodgkin's Lymphoma.
Linked to the drug Plerixafor because the registry names it among its interventions and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Plerixafor, Sanofi and the tag pipeline.
Shares Plerixafor, Filgrastim (G-CSF) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Filgrastim (G-CSF) and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/